ArticleCureus2025
Clinical Utility of Immature Platelet Fraction (IPF) as a Biomarker in the Diagnosis of Acute Coronary Syndrome (ACS).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Acute coronary syndrome (ACS) is a critical medical emergency requiring prompt diagnosis and treatment to prevent severe complications, including death, and the underlying pathology of ACS involves the rupture or erosion of an atheromatous plaque within the coronary arteries. Platelets get consumed in an atherosclerotic blood vessel (artery) soon after the rupture of atherosclerotic plaque, which can result in the release of larger immature platelets from bone marrow. The primary objective of this study was to determine the clinical utility of immature platelet fraction (IPF) as a biomarker in the diagnosis of ACS. As secondary objectives, we tried to determine the association between mean platelet volume (MPV) and IPF in the diagnosis of ACS and to determine the role of IPF in differentiating single vessel disease (SVD), double vessel disease (DVD), and triple vessel disease (TVD). Materials and methods A pilot study was conducted with 15 samples, and the sensitivity of IPF (90%) to diagnose ACS was obtained with a 95% confidence interval and 10% allowable error; the overall minimum sample size came to 53 (including a minimum 35 ACS). Fifty-four patients with chest pain, including patients who presented to the emergency room (ER) and who got admitted in the ward and critical care unit (CCU), satisfying the inclusion criteria, were included in the study. Statistical analysis was done using the IBM SPSS Statistics for Windows, Version 20 (IBM Corp., Armonk, NY). The results are given in mean ± SD for all the continuous variables and in frequency (percentage) for categorical variables. The normality of the data was checked by the Kolmogorov-Smirnov Z test. The receiver operating characteristic (ROC) curve was applied to find an ideal cut-off of IPF for the diagnosis of ACS with respect to ECG and cardiac enzymes. Diagnostic measures such as sensitivity and specificity were applied. To test the statistical significance of the difference in the proportion of IPF and MPV with ACS, the Chi-square test was used, and the same test was used to differentiate SVD, DVD, and TVD using IPF with respect to coronary angiogram (CAG). Pearson's correlation coefficient was applied to find the correlation of IPF with MPV and platelet count, and its statistical significance was checked by linear reg t test. Results Among the 54 participants, 38 (70.4%) were diagnosed with ACS, while 16 (29.6%) were found to have non-cardiac chest pain. The ROC curve was plotted, and a cut-off value of 1.7250% was determined for IPF with a sensitivity of 94.7% and a specificity of 93.7%. The area under the ROC curve (AUC) was 0.984, with a standard error of 0.014 (p < 0.001). There was a strong positive correlation between IPF and MPV (r = 0.731, p < 0.001) in ACS patients. Conclusion Our study demonstrates that IPF and MPV are valuable biomarkers for the diagnosis of ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.